Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014081384> ?p ?o ?g. }
- W2014081384 endingPage "855" @default.
- W2014081384 startingPage "844" @default.
- W2014081384 abstract "Background and Aim: Current practice guidelines recommend that individuals chronically infected with the hepatitis C virus (HCV) be treated with pegylated interferon plus ribavirin. Ribavirin, however, is associated with serious adverse events (AE), especially anemia. We review its mechanism of action, its importance in treating chronic hepatitis C (CHC) patients, the AE associated with its use, and techniques used to lessen these AE. Methods: Medline searches were performed using the keywords ribavirin and hepatitis, together with the keywords mechanism, anemia, liver transplant, renal function, pharmacokinetics, and dose reduction. Searches of abstracts of recent Digestive Diseases Week, American Association for the Study of Liver Diseases, and European Association for the Study of Liver Diseases meetings were also performed. Results: Ribavirin may be effective in treating CHC by affecting the virus or the host; for example by inducing viral mutations, blocking cellular enzymes, or affecting the host immune response. Although the pegylated interferons are the primary drugs used to treat CHC, a combination with ribavirin is more effective than pegylated interferon alone. Ribavirin-associated AE may be lessened by ribavirin dose reductions and by maintenance of the hematocrit. Conclusions: Treatments of ribavirin toxicities, especially anemia, can allow patients to continue full-dose combination therapy with peginterferon and ribavirin, enhancing their probability of attaining a sustained virologic response (SVR). Treatment of CHC should be tailored to individual patients, especially those with renal dysfunction, and should include agents that treat the side-effects of CHC treatment. Monitoring of plasma ribavirin concentrations during treatment may help in the future." @default.
- W2014081384 created "2016-06-24" @default.
- W2014081384 creator A5017882046 @default.
- W2014081384 creator A5056355381 @default.
- W2014081384 date "2008-06-01" @default.
- W2014081384 modified "2023-10-06" @default.
- W2014081384 title "Ribavirin in the treatment of chronic hepatitis C" @default.
- W2014081384 cites W1499427179 @default.
- W2014081384 cites W1515293536 @default.
- W2014081384 cites W1572917101 @default.
- W2014081384 cites W1599050129 @default.
- W2014081384 cites W1709477531 @default.
- W2014081384 cites W1920360815 @default.
- W2014081384 cites W1934976864 @default.
- W2014081384 cites W1963500688 @default.
- W2014081384 cites W1964264521 @default.
- W2014081384 cites W1967080996 @default.
- W2014081384 cites W1969851395 @default.
- W2014081384 cites W1971534251 @default.
- W2014081384 cites W1973933851 @default.
- W2014081384 cites W1974441545 @default.
- W2014081384 cites W1974484952 @default.
- W2014081384 cites W1975782665 @default.
- W2014081384 cites W1976406734 @default.
- W2014081384 cites W1976784383 @default.
- W2014081384 cites W1978339383 @default.
- W2014081384 cites W1982302584 @default.
- W2014081384 cites W1985506908 @default.
- W2014081384 cites W1986032729 @default.
- W2014081384 cites W1990162272 @default.
- W2014081384 cites W1992239172 @default.
- W2014081384 cites W1994227589 @default.
- W2014081384 cites W1994340288 @default.
- W2014081384 cites W1995388272 @default.
- W2014081384 cites W1995568450 @default.
- W2014081384 cites W2000252267 @default.
- W2014081384 cites W2003641083 @default.
- W2014081384 cites W2004200545 @default.
- W2014081384 cites W2007122128 @default.
- W2014081384 cites W2007198955 @default.
- W2014081384 cites W2007209701 @default.
- W2014081384 cites W2015346544 @default.
- W2014081384 cites W2018432327 @default.
- W2014081384 cites W2024049300 @default.
- W2014081384 cites W2024258010 @default.
- W2014081384 cites W2026415957 @default.
- W2014081384 cites W2027545702 @default.
- W2014081384 cites W2027992424 @default.
- W2014081384 cites W2028177473 @default.
- W2014081384 cites W2030805412 @default.
- W2014081384 cites W2033753462 @default.
- W2014081384 cites W2034182580 @default.
- W2014081384 cites W2042185809 @default.
- W2014081384 cites W2043563312 @default.
- W2014081384 cites W2043872599 @default.
- W2014081384 cites W2047208492 @default.
- W2014081384 cites W2050660031 @default.
- W2014081384 cites W2051357230 @default.
- W2014081384 cites W2061294380 @default.
- W2014081384 cites W2067953846 @default.
- W2014081384 cites W2068329523 @default.
- W2014081384 cites W2071586067 @default.
- W2014081384 cites W2071789946 @default.
- W2014081384 cites W2072293369 @default.
- W2014081384 cites W2073081006 @default.
- W2014081384 cites W2078328626 @default.
- W2014081384 cites W2079634214 @default.
- W2014081384 cites W2080419881 @default.
- W2014081384 cites W2084291231 @default.
- W2014081384 cites W2085261733 @default.
- W2014081384 cites W2086274306 @default.
- W2014081384 cites W2086357993 @default.
- W2014081384 cites W2087842843 @default.
- W2014081384 cites W2088146837 @default.
- W2014081384 cites W2090370866 @default.
- W2014081384 cites W2092005960 @default.
- W2014081384 cites W2092710527 @default.
- W2014081384 cites W2093200039 @default.
- W2014081384 cites W2101897708 @default.
- W2014081384 cites W2103932436 @default.
- W2014081384 cites W2105035944 @default.
- W2014081384 cites W2107020066 @default.
- W2014081384 cites W2109666873 @default.
- W2014081384 cites W2112876622 @default.
- W2014081384 cites W2119120658 @default.
- W2014081384 cites W2119226162 @default.
- W2014081384 cites W2119924468 @default.
- W2014081384 cites W2124850017 @default.
- W2014081384 cites W2127685726 @default.
- W2014081384 cites W2129767605 @default.
- W2014081384 cites W2130105663 @default.
- W2014081384 cites W2139166805 @default.
- W2014081384 cites W2143125362 @default.
- W2014081384 cites W2143519512 @default.
- W2014081384 cites W2147121618 @default.
- W2014081384 cites W2153918414 @default.
- W2014081384 cites W2155600971 @default.
- W2014081384 cites W2165715544 @default.